Lakefront Biotherapeutics (LKFT) Current Assets (2014 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Current Assets for 13 consecutive years, with $3.5 billion the latest figure, recorded in Q1 2026.

• Quarterly Current Assets fell 11.85% year-over-year to $3.5 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.5 billion (down 11.85% YoY) and the FY2025 annual result came in at $3.5 billion, down 7.79% from the prior year.
• Current Assets fell to $3.5 billion in Q1 2026 per LKFT's latest filing, from $3.5 billion in the prior quarter.
• Over the last five years, Current Assets for LKFT reached as high as $5.4 billion in Q1 2022 and fell as low as $3.5 billion in Q1 2026.
• A 5-year average of $4.2 billion and a median of $4.1 billion in 2024 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2024 — Current Assets dropped 13.52% — and 2025, when it dropped 7.79%.
• Year by year, Current Assets stood at $4.8 billion in 2022, then decreased by 8.86% to $4.4 billion in 2023, then decreased by 13.52% to $3.8 billion in 2024, then decreased by 7.79% to $3.5 billion in 2025, then declined by 0.61% to $3.5 billion in 2026.
• According to Business Quant data, Current Assets over the past three periods registered $3.5 billion, $3.5 billion, and $3.6 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.